Xrcc4 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| XRCC4 | |
|---|---|
| Gene Symbol | XRCC4 |
| Full Name | X-Ray Repair Cross Complementing 4 |
| Chromosome | 5q14.1 |
| NCBI Gene ID | 7518 |
| OMIM | 604432 |
| Ensembl ID | ENSG00000152457 |
| UniProt ID | Q01426 |
| Associated Diseases | Cancer, Immunodeficiency, Neurodegeneration |
X-Ray Repair Cross Complementing 4 (XRCC4) is a core component of the non-homologous end joining (NHEJ) DNA double-strand break repair pathway. As the essential binding partner of DNA Ligase IV (LIG4), XRCC4 plays a critical role in joining DNA ends during NHEJ and is absolutely required for V(D)J recombination in developing lymphocytes. XRCC4 deficiency in humans causes severe combined immunodeficiency (SCID) with microcephaly, while complete knockout in mice is embryonic lethal. Beyond its well-established role in DNA repair, XRCC4 has been implicated in neurodegeneration, with altered expression and function observed in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
XRCC4 functions as the essential co-factor for DNA Ligase IV in the NHEJ pathway. The XRCC4 protein forms a stable heterotetramer with LIG4, which is required for:
The XRCC4-LIG4 complex is recruited to DNA double-strand breaks by the Ku70/Ku80 heterodimer, which binds to free DNA ends and initiates the NHEJ repair process. XRCC4 interacts directly with Ku and DNA-PKcs, positioning the ligase complex at the repair site. Additional processing by Artemis endonuclease and polymerases mu/lambda prepares the DNA ends, after which XRCC4-LIG4 catalyzes final ligation.
XRCC4 is absolutely essential for V(D)J recombination, the site-specific DNA rearrangement process that generates antibody and T-cell receptor diversity. During V(D)J recombination:
Mutations in XRCC4 cause SCID with impaired V(D)J recombination, similar to LIG4 deficiency.
Beyond canonical NHEJ, XRCC4 has been implicated in:
Biallelic XRCC4 mutations cause a form of SCID characterized by:
This phenotype overlaps with LIG4 syndrome, reflecting their functional partnership.
Alzheimer's Disease (AD):
Parkinson's Disease (PD):
Amyotrophic Lateral Sclerosis (ALS):
Ataxia-Telangiectasia (AT):
XRCC4 polymorphisms have been associated with cancer risk:
XRCC4 is ubiquitously expressed with high levels in:
In the brain, XRCC4 is expressed in:
Expression is generally higher in proliferating cells but is maintained in post-mitotic neurons for ongoing DNA repair.
Strategies targeting DNA repair in neurodegeneration include:
XRCC4 is a potential therapeutic target:
The study of Xrcc4 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.